Huiting Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huiting Guan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ke-Jie He
The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, China
2 shared publications Cheng Jiang
Department of Respiratory Medicine, Hubei Hospital of Traditional Chinese Medicine Hubei University of Chinese Medicine Wuhan Hubei P. R. China
1 shared publicationCong He
Department of Respiratory Medicine, Hubei Hospital of Traditional Chinese Medicine Hubei University of Chinese Medicine Wuhan Hubei P. R. China
1 shared publicationDajun Chen
Quzhou People’s Hospital, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou, China
1 shared publication- Dajun Chen
The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, Zhejiang, China
1 shared publication Haitao Wang
Department of Cardiology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (22) , e49068
Global burden of type 2 diabetes mellitus attributable to household air pollution from solid fuels, 1990 to 2021, and projections to 2044: An epidemiological analysis in adults aged 55 years and older
This study utilized the 2021 Global Burden of Disease data to analyze the global trends of type 2 diabetes mellitus (T2DM) burden attributable to household air pollution from solid fuels (HAPSF) in individuals aged 55 and above. The background emphasizes the significance of HAPSF as a global health issue, particularly in low and low-middle Socio-demographic Index (SDI) regions. The study employed geospatial visualization and joinpoint regression analysis to examine the trends in T2DM-related deaths and disability-adjusted life years (DALYs) from 1990 to 2021. The methodology involved a detailed exploration of the Global Burden of Disease database, along with comparative analysis of data across different SDI regions. The study showed a global pattern of rising then falling T2DM deaths and DALYs. Low SDI areas saw DALYs increase from 1990 to 1995, and low-middle SDI regions from 2005 to 2008. High SDI countries had DALY decreases, with aging a major influence. Age-period analysis indicated high SDI regions’ DALYs were higher recently, especially affecting the elderly. The study anticipates a rise in T2DM burden from HAPSF, notably in low and low-middle SDI areas, due to population growth and epidemiological shifts. It calls for targeted policies and interventions to mitigate this burden. Projections also indicate an initial T2DM case increase in the 65 to 69 age group, followed by a decline.
- 29 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (22) , e49068
Open AccessGlobal burden of type 2 diabetes mellitus attributable to household air pollution from solid fuels, 1990 to 2021, and projections to 2044: An epidemiological analysis in adults aged 55 years and older
This study utilized the 2021 Global Burden of Disease data to analyze the global trends of type 2 diabetes mellitus (T2DM) burden attributable to household air pollution from solid fuels (HAPSF) in individuals aged 55 and above. The background emphasizes the significance of HAPSF as a global health issue, particularly in low and low-middle Socio-demographic Index (SDI) regions. The study employed geospatial visualization and joinpoint regression analysis to examine the trends in T2DM-related deaths and disability-adjusted life years (DALYs) from 1990 to 2021. The methodology involved a detailed exploration of the Global Burden of Disease database, along with comparative analysis of data across different SDI regions. The study showed a global pattern of rising then falling T2DM deaths and DALYs. Low SDI areas saw DALYs increase from 1990 to 1995, and low-middle SDI regions from 2005 to 2008. High SDI countries had DALY decreases, with aging a major influence. Age-period analysis indicated high SDI regions’ DALYs were higher recently, especially affecting the elderly. The study anticipates a rise in T2DM burden from HAPSF, notably in low and low-middle SDI areas, due to population growth and epidemiological shifts. It calls for targeted policies and interventions to mitigate this burden. Projections also indicate an initial T2DM case increase in the 65 to 69 age group, followed by a decline.
- Open Access
- 11 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Global disparities in liver cancer burden: an epidemiological and socioeconomic analysis using GBD 1990–2021 data
Background Liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma as defined in the Global Burden of Disease (GBD) framework, remains a major contributor to global disease burden with pronounced socioeconomic disparities. However, long-term global patterns, socioeconomic gradients, and their demographic and epidemiological drivers remain incompletely characterized. This study assessed global and regional trends in liver cancer burden using GBD 2021 data. Methods Liver cancer disability-adjusted life years (DALYs) were estimated for 204 countries from 1990 to 2021. Temporal trends and contributing factors were examined using Joinpoint regression, age–period–cohort analysis, decomposition analysis, and frontier analysis. Results Globally, liver cancer DALYs declined between 1990 and 2021, with an average annual percent change (AAPC) of − 0.46. Declines were observed in high SDI (AAPC − 0.42), high-middle SDI (− 0.63), middle SDI (− 0.72), and low SDI regions (− 0.80), whereas low-middle SDI countries experienced a modest increase (AAPC 0.08). Decomposition analysis showed that population growth and aging were the primary drivers of global DALY increases, while epidemiological changes accounted for most declines in high SDI regions. Risk factor–specific analyses revealed declining hepatitis B–attributable DALYs globally (AAPC − 0.79), contrasted by rising MASH-attributable DALYs (AAPC 0.60), particularly in low-middle SDI countries. Frontier analysis demonstrated substantial cross-country variability in performance at comparable socioeconomic levels. Conclusion Global liver cancer burden has declined overall but remains unevenly distributed, driven by divergent demographic transitions, etiologic profiles, and socioeconomic context. These findings highlight substantial unrealized potential for burden reduction, particularly in low and low-middle SDI countries.
- 11 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessGlobal disparities in liver cancer burden: an epidemiological and socioeconomic analysis using GBD 1990–2021 data
Background Liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma as defined in the Global Burden of Disease (GBD) framework, remains a major contributor to global disease burden with pronounced socioeconomic disparities. However, long-term global patterns, socioeconomic gradients, and their demographic and epidemiological drivers remain incompletely characterized. This study assessed global and regional trends in liver cancer burden using GBD 2021 data. Methods Liver cancer disability-adjusted life years (DALYs) were estimated for 204 countries from 1990 to 2021. Temporal trends and contributing factors were examined using Joinpoint regression, age–period–cohort analysis, decomposition analysis, and frontier analysis. Results Globally, liver cancer DALYs declined between 1990 and 2021, with an average annual percent change (AAPC) of − 0.46. Declines were observed in high SDI (AAPC − 0.42), high-middle SDI (− 0.63), middle SDI (− 0.72), and low SDI regions (− 0.80), whereas low-middle SDI countries experienced a modest increase (AAPC 0.08). Decomposition analysis showed that population growth and aging were the primary drivers of global DALY increases, while epidemiological changes accounted for most declines in high SDI regions. Risk factor–specific analyses revealed declining hepatitis B–attributable DALYs globally (AAPC − 0.79), contrasted by rising MASH-attributable DALYs (AAPC 0.60), particularly in low-middle SDI countries. Frontier analysis demonstrated substantial cross-country variability in performance at comparable socioeconomic levels. Conclusion Global liver cancer burden has declined overall but remains unevenly distributed, driven by divergent demographic transitions, etiologic profiles, and socioeconomic context. These findings highlight substantial unrealized potential for burden reduction, particularly in low and low-middle SDI countries.
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Vasoactive–Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real‐World Dynamic Data
Background: In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive–inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive–inotropic score reduction rate (VRR) to measure VIS changes over time and explore its association with mortality in CS patients. Methods: We performed a retrospective observational study using two large intensive care databases (MIMIC‐IV and eICU). Adult patients with CS receiving vasoactive–inotropic agents within 24 h after ICU admission were included. VIS was calculated using the updated VIS 2020, and VRR was defined to capture the relative change in VIS over time. Patients were categorized into VIS‐decreasing and VIS‐increasing groups. The primary outcome was in‐hospital mortality; secondary outcomes were intensive care unit (ICU) and 28‐day mortality (28‐day mortality only for the MIMIC‐IV database). Associations between VRR and outcomes were examined using four models: (1) log‐rank analysis, (2) Cox model adjusted for all covariates, (3) Cox model adjusted for covariates selected by univariable analyses, and (4) Cox model adjusted for covariates selected by a random forest algorithm. Results: A total of 3170 adult CS patients were analyzed. All models in both MIMIC‐IV and eICU showed that an increasing VIS over time was consistently associated with higher in‐hospital, ICU, and 28‐day mortality compared with a decreasing VIS in the MIMIC‐IV cohort ( p < 0.001). These findings were reproduced in the external eICU cohort for ICU and in‐hospital mortality ( p < 0.001), supporting the robustness and generalizability of VRR as a prognostic indicator across heterogeneous ICUs. Conclusions: In adult CS patients, a greater reduction in VIS over time is strongly associated with lower mortality. VRR provides a simple, dynamic summary of vasoactive trajectories and may serve as a useful adjunct for risk stratification alongside other clinical and biochemical markers, although prospective validation is warranted.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Open AccessVasoactive–Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real‐World Dynamic Data
Background: In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive–inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive–inotropic score reduction rate (VRR) to measure VIS changes over time and explore its association with mortality in CS patients. Methods: We performed a retrospective observational study using two large intensive care databases (MIMIC‐IV and eICU). Adult patients with CS receiving vasoactive–inotropic agents within 24 h after ICU admission were included. VIS was calculated using the updated VIS 2020, and VRR was defined to capture the relative change in VIS over time. Patients were categorized into VIS‐decreasing and VIS‐increasing groups. The primary outcome was in‐hospital mortality; secondary outcomes were intensive care unit (ICU) and 28‐day mortality (28‐day mortality only for the MIMIC‐IV database). Associations between VRR and outcomes were examined using four models: (1) log‐rank analysis, (2) Cox model adjusted for all covariates, (3) Cox model adjusted for covariates selected by univariable analyses, and (4) Cox model adjusted for covariates selected by a random forest algorithm. Results: A total of 3170 adult CS patients were analyzed. All models in both MIMIC‐IV and eICU showed that an increasing VIS over time was consistently associated with higher in‐hospital, ICU, and 28‐day mortality compared with a decreasing VIS in the MIMIC‐IV cohort ( p < 0.001). These findings were reproduced in the external eICU cohort for ICU and in‐hospital mortality ( p < 0.001), supporting the robustness and generalizability of VRR as a prognostic indicator across heterogeneous ICUs. Conclusions: In adult CS patients, a greater reduction in VIS over time is strongly associated with lower mortality. VRR provides a simple, dynamic summary of vasoactive trajectories and may serve as a useful adjunct for risk stratification alongside other clinical and biochemical markers, although prospective validation is warranted.
- 5 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (4) , e28706
Integrative bulk and single‐cell transcriptome profiling analysis reveals IFI27 as a novel interferon‐stimulated gene in dengue
The dengue virus (DENV) is a public health threat to humans. Increased vascular permeability, coagulopathy, and hemorrhagic diathesis are the pathophysiological hallmarks of severe dengue. However, although the interferon (IFN)‐mediated innate immune response forms the backbone of cell‐autonomous defense against pathogens, the exact IFN‐stimulated genes (ISGs) involved in DENV infection remain to be determined. The present study collected transcriptomic data sets of peripheral blood mononuclear cells from DENV patients and healthy volunteers from public data repositories. Also, lentivirus and plasmid were used to overexpress and knockdown IFI27. Initially, differentially expressed genes were filtered, and gene set enrichment analysis (GSEA) was performed to assess related pathways. Subsequently, the least absolute shrinkage and selection operator regression and support vector machine‐recursive feature elimination algorithms were used to screen crucial genes. The receiver operating characteristic curve analysis was then employed to test diagnostic efficacy. Next, CIBERSORT was used to analyze immune infiltration in 22 immune cell subsets. Additionally, to dissect high‐resolution molecular phenotypes directly from individual cells and the cellular interactions between immune cell subpopulations, single‐cell RNA sequencing (scRNA‐seq) was performed. We found that the IFN‐stimulated gene IFN‐α‐inducible protein 27 (IFI27) was highly expressed in dengue patients by leveraging bioinformatics analysis and machine learning algorithms. This finding was further validated in two independent published databases. In addition, IFI27 overexpression positively regulated DENV‐2 infection, whereas IFI27 knockdown has the opposite effect. Consistently, scRNA‐seq analysis supported this conclusion, along with further dissection of increased IFI27 expression mainly concentrated in monocytes and plasmacytoid dendritic cells. We also demonstrated that IFI27 inhibited dengue infection. Moreover, IFI27 was positively correlated with monocytes, M1 macrophages, activated dendritic cells, plasma cells, and resting mast cells and negatively correlated with CD8 T cells, γδ T cells, and naïve B cells. GSEA revealed that IFI27 was primarily enriched in the innate immune response, regulation of the viral life cycle, and JAK‐STAT signaling pathway. Notably, the interactions between LGALS9 and its receptor CD47 were markedly increased in dengue patients compared to healthy controls, based on cell‐cell communication analysis. Our findings reveal, for the first time, that IFI27 is a key ISG in DENV infection. Given that the innate immune system plays a significant role in antagonizing DENV invasion, while ISGs are the ultimate antiviral effectors, IFI27 may serve as a potential diagnostic marker and therapeutic target in dengue, although further validation is warranted.
- 5 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (4) , e28706
Integrative bulk and single‐cell transcriptome profiling analysis reveals IFI27 as a novel interferon‐stimulated gene in dengue
The dengue virus (DENV) is a public health threat to humans. Increased vascular permeability, coagulopathy, and hemorrhagic diathesis are the pathophysiological hallmarks of severe dengue. However, although the interferon (IFN)‐mediated innate immune response forms the backbone of cell‐autonomous defense against pathogens, the exact IFN‐stimulated genes (ISGs) involved in DENV infection remain to be determined. The present study collected transcriptomic data sets of peripheral blood mononuclear cells from DENV patients and healthy volunteers from public data repositories. Also, lentivirus and plasmid were used to overexpress and knockdown IFI27. Initially, differentially expressed genes were filtered, and gene set enrichment analysis (GSEA) was performed to assess related pathways. Subsequently, the least absolute shrinkage and selection operator regression and support vector machine‐recursive feature elimination algorithms were used to screen crucial genes. The receiver operating characteristic curve analysis was then employed to test diagnostic efficacy. Next, CIBERSORT was used to analyze immune infiltration in 22 immune cell subsets. Additionally, to dissect high‐resolution molecular phenotypes directly from individual cells and the cellular interactions between immune cell subpopulations, single‐cell RNA sequencing (scRNA‐seq) was performed. We found that the IFN‐stimulated gene IFN‐α‐inducible protein 27 (IFI27) was highly expressed in dengue patients by leveraging bioinformatics analysis and machine learning algorithms. This finding was further validated in two independent published databases. In addition, IFI27 overexpression positively regulated DENV‐2 infection, whereas IFI27 knockdown has the opposite effect. Consistently, scRNA‐seq analysis supported this conclusion, along with further dissection of increased IFI27 expression mainly concentrated in monocytes and plasmacytoid dendritic cells. We also demonstrated that IFI27 inhibited dengue infection. Moreover, IFI27 was positively correlated with monocytes, M1 macrophages, activated dendritic cells, plasma cells, and resting mast cells and negatively correlated with CD8 T cells, γδ T cells, and naïve B cells. GSEA revealed that IFI27 was primarily enriched in the innate immune response, regulation of the viral life cycle, and JAK‐STAT signaling pathway. Notably, the interactions between LGALS9 and its receptor CD47 were markedly increased in dengue patients compared to healthy controls, based on cell‐cell communication analysis. Our findings reveal, for the first time, that IFI27 is a key ISG in DENV infection. Given that the innate immune system plays a significant role in antagonizing DENV invasion, while ISGs are the ultimate antiviral effectors, IFI27 may serve as a potential diagnostic marker and therapeutic target in dengue, although further validation is warranted.